Hunt Anthony

Director Hunt Anthony sells 20,000 shares (20.0K) at blended $154.61 for $3.1M; 5 similar sales on 2025-11-12; RGEN at depressed valuation (P/E: 5079.00).

Hunt Anthony executed 7 separate sales totaling 20,000 shares for $3,092,278.36 on 2025-11-13, reducing his holdings by 19.3% to 83,695 shares. This follows 5 prior sales on 2025-11-12, indicating a concentrated two-day liquidation pattern. The blended average sale price of $154.61 is above the current price of $152.37, though the stock remains within its 52-week range (-12.6% from the $174.24 high) and up 22.5% over 90 days. RGEN's fundamentals present a warning: the company reported a negative full-year net income despite $188.8M in quarterly revenue, and its P/E of 5079.00 reflects minimal profitability. Across his cross-ticker track record, Hunt's 20 prior sells averaged -6.0% 90-day returns with a 44.44% well-timed rate; no measurable outcomes yet exist for his 5 prior RGEN trades on 2025-11-12. The scale and timing of this director-level liquidation warrants monitoring given the company's unprofitable status and elevated valuation metrics.

Director Hunt Anthony sells 25,000 RGEN shares across 5 transactions on 2025-11-12 for $3.9M at avg $156.88

Hunt Anthony, a director at Repligen, executed 5 separate sales totaling 25,000 shares for $3,921,939.67 on 2025-11-12, reducing his holdings by -19.9% from 125,743 to 100,743 shares. The sales occurred at prices ranging from $154.92 to $158.51, above the current price of $150.56 and well above the 52-week low of $108.89, positioning the exit in the upper range of recent valuations. The company carries significant valuation stress: its P/E ratio of 5018.67 reflects near-zero profitability (net income of $14,911,000 on $188.8M quarterly revenue), and it was unprofitable over the most recent full fiscal year, indicating fundamental challenges beyond this single trading event. His cross-ticker track record shows a 28.57% well-timed rate on prior sells (negative 90d average return of -3.3%), but this is his first measurable sale at RGEN, so same-ticker precedent is absent.

Director Hunt Anthony sold 29,111 shares at $120.52 avg for $3.5M on 2025-09-10

Hunt Anthony, a Director at Repligen Corp, executed 6 separate sales totaling 29,111 shares for $3,508,388.91 on 2025-09-10, reducing his holdings by 22.4% from 129.9K to 100.7K shares. The blended average sale price of $120.52 sits within the 52-week range but 31.4% below the 52-week high of $174.24, reflecting the stock's recent weakness (down 6.3% over 90 days and 1.6% over 30 days). His cross-ticker track record shows a 47.37% well-timed rate on 19 prior sells, but at Repligen specifically, 0 of 5 prior sales (all on 2025-05-15) were well-timed at the 90-day mark. The sale occurs as the company reported annual revenue growth of -0.7% and full-year net income was negative, signaling operational headwinds that warrant investor attention.

Director Hunt Anthony sold 26,447 shares (26.4K) for $3,271,687.92 in 5 separate sales on 2025-05-15 at $122.66–$127.00; stock down -4.2% (30d), -13.9% (90d) from transaction date.

Hunt Anthony, Director at Repligen Corp, executed 5 separate sales totaling 26.4K shares for $3.3M, reducing his holdings by -19.4% (from 136.3K to 109.9K shares). His cross-ticker track record shows 19 prior sells with a 61.54% well-timed rate and average 90-day returns of -5.4%, indicating modest historical accuracy in sell timing. However, at RGEN specifically, all 5 of his prior measurable trades (conducted 2025-03-17) showed negative 30-day returns ranging -10.8% to -14.0%, with none yet measurable at 90 days. The company reported full-year net loss (unprofitable) and negative revenue growth of -0.7%, while trading -28.1% below its 52-week high, providing a backdrop of financial underperformance. The timing and volume of this liquidation warrant scrutiny given the broader fundamental and technical weakness in the name.

Director Hunt Anthony sells 26,756 shares of RGEN for $4.1M across 6 transactions on 2025-03-17

Hunt Anthony, a Director, executed 6 separate sales totaling 26,756 shares for $4,080,663.26 on 2025-03-17, reducing his holdings by 16.4% to 136,301 shares at a blended average price of $152.51. The current stock price of $144.88 is 27.5% below the 52-week high of $199.74, and the company reported negative net income of $-654,000.00 for the latest quarter with annual revenue declining 0.7% year-over-year. At this specific ticker (RGEN), Anthony's prior 5 sales show no well-timed 90-day outcomes, with all 5 prior sells followed by positive 90-day returns, yet this large stake reduction occurs as the stock trades significantly below its 52-week peak.

Director Hunt Anthony sold 24,246 shares of RGEN for $3.4M at $139.67; stock down -31.6% from 52-week high amid -20.3% annual revenue decline.

Hunt Anthony, a director at Repligen Corp, sold 24,246 shares for $3,386,438.82 at $139.67 on 2024-11-21, reducing his position by 14.8% from 164,086 to 139,840 shares. The sale occurs in the context of weak fundamentals: the company reported revenue of $154,871,000.00 in the latest quarter with net loss of $-654,000.00, and annual revenue contracted 20.3% year-over-year. The stock is trading at $142.58 (current), representing a -31.6% decline from its 52-week high of $208.42. Anthony's cross-ticker track record shows a 100% win rate on his 18 prior sales with an average 90-day return of -18.3%, indicating consistent execution in selling before declines; his same-ticker history shows four prior sales on 2024-09-10 that declined 6.4% to 8.3% over 30 days. This sale extends a pattern of director liquidity at depressed valuations relative to recent highs.

Director Hunt Anthony sold 22,191 shares at $145.37 avg for $3.2M on 2024-09-10; stock down 31.9% from high.

Hunt Anthony executed 4 separate sales totaling 22,191 shares for $3,225,927.40 on 2024-09-10, reducing his holdings by 13.7% from 162,031 to 139,840 shares. The sales occurred at prices ranging from $143.77 to $146.67, with a blended average of $145.37, against a current price of $141.93 and a 52-week high of $208.42. Across his open-market history, Anthony's 14 prior sells showed a 100% well-timed rate at the 90-day mark, with an average 90-day return of -18.3%, and at RGEN specifically, all 5 prior trades (including 4 prior sales from May 2024) were well-timed at 90 days. The company faces significant operational headwinds: FY revenue declined 20.3% year-over-year, annual net income is $3.3M on $154.1M revenue (margin of 2.2%), and the stock trades at a 189.24 P/E despite current weakness. This sale follows a pattern of disciplined exits, though timing characterization must remain observational given the discretionary nature of this filing.

CEO Hunt Anthony bought 2,000 shares of RGEN at $124.08 on 2024-06-14; stock down 39.7% from 52-week high

Hunt Anthony, RGEN's CEO, purchased 2,000 shares at $124.08 on 2024-06-14, increasing his holdings to 165,177 shares. The transaction occurs during a steep drawdown: the stock has fallen 39.7% from its 52-week high of $208.42 and declined 28.6% over the prior 30 days. At the same time, RGEN's fundamentals are under pressure, with annual revenue growth of -20.3% and a P/E of 465.26. A cluster buy pattern (2 other insiders also purchased within 14 days) suggests coordinated or coincidental accumulation. However, the CEO's prior sales at this ticker (5 consecutive sells on 2024-05-21) remain recent and their outcomes are not yet measurable, limiting the ability to assess whether this buy reverses a preceding divestment decision or reflects a distinct conviction shift.